Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Univar’s Cufence Approved In EU For Wilson’s Disease, But Loses Orphan Status

Executive Summary

Cufence, which has just been authorized for EU-wide marketing, is one of two trientine products for Wilson’s disease to lose their orphan designation.

You may also be interested in...



EU Ruling Raises New Questions For Orphan Designation

An EU court has upheld a decision to revoke the orphan designation awarded to GMP-Orphan's trientine product for Wilson's disease, saying that the product no longer met the “significant benefit” criterion on the grounds of lack of availability of another drug. The case has raised questions about the level of evidence needed to justify a significant benefit. 

EU Approval Recommendations: Strong Showing From Orphans & Biosimilars

The CHMP has recommended 11 products for approval at its latest meeting, including four orphan medicines, three biosimilars and two generics. It also recommended harmonizing the product labeling for two etoposide products.

New EU Patent System On Course For End Of 2020, Says EPO

Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.

Topics

UsernamePublicRestriction

Register

PS140646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel